Skip to main content
. 2021 May 13;21:161. doi: 10.1186/s12890-021-01527-1

Table 3.

Patient demographic and clinical information

Variable All VAP
n = 45
No VAP
n = 40
p-value
Age, years, mean (SD) 46.9 (18.9) 44.2 (20.7) 49.9 (16.4) 0.159a
Male, N (%) 62 (72.9) 33 (73.3) 29 (72.5) 0.931c
Admission indication, N (%) 0.652c
Trauma 54 (63.5) 30 (66.7) 24 (60)
Post-operative 31 (36.5) 15 (33.3) 16 (40)
Comorbidities, yes, N (%) 0.932b
ARDS 7 (8.2) 3 (6.7) 4 (10)
Cancer 13 (15.3) 6 (13.3) 7 (17.5)
COPD 7 (8.2) 4 (8.9) 3 (7.5)
CHF 24 (28.2) 13 (28.9) 11 (27.5)
ESRD 14 (16.5) 9 (20) 5 (12.5)
Multiple trauma 20 (23.5) 10 (22.2) 10 (25)
Positive tracheal culture, N (%) 69 (81.2) 40 (88.9) 29 (72.5) 0.093c
MDR organism, yes, N (%) 31 (36.5) 17 (37.8) 14 (35) 0.825c
Procalcitonin, ng/mL, mean (SD) 4.03 (4.68) 3.53 (3.6) 4.6 (5.6) 0.308a
APACHE II, mean (SD) 18.1 (2.84) 17.9 (3.43) 18.4 (1.98) 0.399a
Duration of intubation, hours, mean (SD) 177.1 (39.61) 176.02 (38.7) 178.32 (41.09) 0.791a
Reintubation, N (%) 32 (37.6) 14 (31.1) 18 (45) 0.262c
MV duration prior to VAP, hours, median (IQR) 72 (54–87.5) 72 (52–87.5) 72 (64.5–88.5) 0.639a
ICU duration prior to developing VAP, days, median (IQR) 7 (6–8) 7 (6–8.5) 7 (6–8) 0.118a
VAP timing, mean (SD)
Early (< 5 days) 15 (33.3)
Late (≥ 5 days) 30 (66.7)
Length-of-stay, days, mean (SD)
ICU LOS 9.8 (3.0) 13.13 (3.27) 12.72 (2.75) 0.538a
Non-ICU LOS 15.4 (3.1) 12.67 (3.34) 11.96 (2.99) 0.320a
Mortality, N (%)
ICU 17 (20) 8 (17.8) 9 (22.5) 0.787c
Hospital 22 (25.9) 12 (26.7) 10 (25) 0.861c

VAP: ventilator-associated pneumonia; IQR: interquartile range; MDR: multiple drug resistant; APACHE: Acute Physiology and Chronic Health Evaluation; ICU: intensive care unit; VAP: ventilator-associated pneumonia; LOS: length-of-stay

aIndependent sample t-test

bFisher exact test

cChi-square